德琪（浙江）医药科技有限公司 Deqi (zhejiang) Pharmaceutical Technology Co. LTD
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Antengene Announces One Oral and Three Poster Presentations at ASCO 2024 2024-04-25 20:00
Antengene Presents Four Preclinical Posters at AACR 2024 2024-04-06 08:30
Antengene Announces Full Year 2023 Financial Results, Highlights Clinical Progress Across First-in-Class, Best-in-Class Pipeline 2024-03-22 18:00
Antengene Initiates Phase II Dose Expansion Study of Claudin 18.2 ADC ATG-022 in China and Australia 2024-03-20 20:30
Antengene Publishes Preclinical Paper on PD-L1/4-1BB Bispecific Antibody ATG-101 in Renowned Oncology Journal Cancer Research 2024-03-20 08:30
Antengene to Present Four Preclinical Abstracts at AACR 2024, Highlighting Focus on Cancer Immunology, Targeted Agents and Novel Technology Platforms 2024-03-06 08:30
Antengene Announces Inclusion of XPOVIO® (selinexor) in 2023 China's National Reimbursement Drug List 2023-12-14 09:55
Antengene Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States 2023-12-11 08:30
Antengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma 2023-12-06 17:00
Antengene Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day 2023-11-17 08:00
Antengene to Host 2023 R&D Day and Discuss Key Data with KOLs 2023-11-08 08:30
Antengene Presents Results from Five Investigational Programs at 2023 SITC Annual Meeting 2023-11-01 08:30
Antengene To Present Results From Five Studies at 2023 SITC Annual Meeting 2023-09-28 08:30
Antengene Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031 2023-09-21 18:05
Antengene Announces Interim Financial Results for 2023 with New Clinical Data Highlighting the Growing Value of Its Pipeline 2023-08-25 19:37
Antengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor XPOVIO®(selinexor) in the Mainland of China 2023-08-11 08:00
Antengene Announces First Patient Dosed in the Nivolumab Combination Portion of the Clinical Study Evaluating the ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors in the United States 2023-07-18 08:30
Antengene Announces XPOVIO® Regulatory Approval in Hong Kong for the Treatment of Relapsed and/or Refractory Multiple Myeloma 2023-07-17 08:30
Antengene Announces XPOVIO® plus Bortezomib and Dexamethasone Included for Reimbursement by the PBS in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma 2023-06-01 10:09
Antengene To Present Latest Results from TORCH-2 Study of ATG-008 in Advanced Solid Tumors in Poster Discussion at ASCO 2023 2023-05-26 09:41
1 2 3 4 5 8